1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial
Authors:
- 16 July 2026
- journal article
- Published by Elsevier in The Lancet
- Vol. 408 (10553) , 440-452
Abstract
No abstract availableKeywords
Funding Information
- Abbott Japan
This publication has 35 references indexed in Scilit:
- Integrated Care for Atrial Fibrillation Using the ABC Pathway in the Prospective APHRS-AF RegistryJACC: Asia, 2023
- Adverse 30-Day Clinical Outcomes and Long-Term Mortality Among Patients With Preprocedural Atrial Fibrillation Undergoing Percutaneous Coronary InterventionHeart, Lung and Circulation, 2022
- Clinical Significance of Atrial Fibrillation Status in Patients With Percutaneous Coronary InterventionCJC Open, 2021
- Edoxaban affects TRAP-dependent platelet aggregationJournal of Thrombosis and Thrombolysis, 2020
- Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIJAMA, 2019
- First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregationJournal of Thrombosis and Thrombolysis, 2018
- Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent mannerJournal of Thrombosis and Thrombolysis, 2017
- Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCIJACC, 2016
- Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary InterventionJACC, 2009
- Comparative analysis of two ratesStatistics in Medicine, 1985